William Gibson
Family Medicine · Snead, ALNPI 1083609606
Payments from drug & device makers
Across 59 payments — averaging $20.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$212
- Otsuka America Pharmaceutical, Inc.$115
- Novo Nordisk$111
- AstraZeneca$93
- AbbVie$93
- Biocryst US Sales Co., LLC$89
- plus $489 from 18 others
What the payments were for
- Food & beverage$1,201100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 9 | $212 |
| Otsuka America Pharmaceutical, Inc. | 2 | $115 |
| Novo Nordisk | 8 | $111 |
| AstraZeneca | 5 | $93 |
| AbbVie(2 entities) | 6 | $93 |
| Biocryst US Sales Co., LLC | 2 | $89 |
| Esperion Therapeutics, Inc. | 4 | $70 |
| Avanir Pharmaceuticals, Inc. | 3 | $61 |
| Regeneron Healthcare Solutions, Inc. | 1 | $38 |
| Pharming Healthcare, Inc. | 2 | $34 |
| Novartis | 2 | $30 |
| Lilly USA, LLC | 2 | $30 |
| Sumitomo Pharma America, Inc. | 1 | $27 |
| Shire North American Group Inc | 2 | $24 |
| Amarin Pharma, Inc. | 1 | $21 |
| Melinta Therapeutics, LLC | 1 | $20 |
| Roche Diagnostics Corporation | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| GSK | 1 | $18 |
| Johnson & Johnson | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
| Neurocrine Biosciences, Inc. | 1 | $14 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$103
How this compares
$1,201 in reported general payments places this provider in the 60th percentile of 1,680 family medicine providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 477 | $109,361 |
| IngrezzaValbenazine Tosylate | 20 | $55,971 |
| JardianceEmpagliflozin | 219 | $49,991 |
| MounjaroTirzepatide | 42 | $46,176 |
| XifaxanRifaximin | 25 | $40,359 |
| VraylarCariprazine Hcl | 65 | $40,278 |
| JanuviaSitagliptin Phosphate | 217 | $40,195 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 51 | $35,163 |
| Risperdal ConstaRisperidone Microspheres | 14 | $30,841 |
| XareltoRivaroxaban | 123 | $30,622 |
| OzempicSemaglutide | 19 | $22,315 |
| FarxigaDapagliflozin Propanediol | 36 | $18,493 |
| LinzessLinaclotide | 32 | $18,123 |
| MyrbetriqMirabegron | 82 | $15,008 |
| Pantoprazole Sodium | 898 | $14,226 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Linzess, Ubrelvy | $93 | $67,747113 claims |
| Johnson & JohnsonRisperdal Consta, Xarelto | $17 | $61,463137 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $14 | $55,97120 claims |
| Lilly USA, LLCMounjaro | $30 | $46,17642 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $18 | $45,28574 claims |
| MerckJanuvia | $14 | $40,195217 claims |
| Novo NordiskOzempic, Levemir | $111 | $29,00076 claims |
| AstraZenecaFarxiga | $93 | $18,49336 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $61 | $11,07630 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $115 | $7,02719 claims |
| Sanofi-aventis U.S. LLCLantus | $15 | $6,93271 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $27 | $5,84524 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Snead
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
- Aaron KarrSheffield$3.1M
- Nidal MorrarFoley$3M
- Timothy HowardHuntsville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.